Pinotbio, which is jointly developing antibody-drug conjugate (ADC) drugs with Celltrion and Lotte Biologics, has begun developing a manufacturing process for Trop-2-targeted ADCs.Pinotbio said Tuesday that it had been selected as the lead research and development organization for the national task
AriBio said on Tuesday it has signed an agreement to take over the management of Solux, a Kosdaq-listed company. AriBio said in a public filing that its CEO Jung Jae-joon will secure management control of Solux's largest shareholder, CEO Kim Bok-deok, and that Solux will raise 50 billion won ($37.3
Ildong Bioscience said Monday that it participated in Vitafoods Europe 2023 and advertised probiotics-related materials, products, and technology.Vitafoods Europe is the continent’s largest exhibition of healthcare foods, beverages, and functional foods. This year’s event was held in Geneva, Switzer
On Monday, the Korean Advanced Institute of Science and Technology (KAIST) announced that its researchers have identified genomic disruptions in human colorectal epithelial cells, confirming that the activation of L1 retrotransposable or "jumping" genes is linked to aging and carcinogenesis.The acti
Researchers at Kookmin University said Koreans’ birth weight (BW) and gestational period decreased by 3 grams and 0.28 days, respectively, each year for the past 20 years.Professor Hur Yoon-mi of General Education at Kookmin University conducted the study by analyzing Korean birth weight data obtain
Celltrion Healthcare said it won bids to supply its Avastin biosimilar Vegzelma (ingredient: bevacizumab) to Italy and Belgium to treat metastatic colorectal and breast cancer.Most recently, the company won bids in three provinces in Italy -- Lombardy, Emilia Romagna, and Toscana -- in the first qua
Pinotbio, a medical and pharmaceutical developer that attracted investment in partnership with Celltrion and Lotte Biologics, has set about to prepare for its listing on the Kosdaq market.Amid the increasing interest in antibody-drug conjugate (ADC) technology, industry insiders pay attention to whe
The share prices of Bioneer, which drew attention by releasing a shampoo brand that relieves hair loss, plunged on Monday, making investors and analysts curious about its background.Bioneer stocks ended Monday’s trading at 51,300 won ($38.7) a share, down 29.92 percent from 73,200 won the previous t
Celltrion, a Korean biopharma giant, has announced that it will no longer pursue the acquisition of the biopharma solutions unit of Baxter International, a U.S.-based healthcare company.Celltrion has revealed through a public filing on Tuesday that it had contemplated the acquisition of Baxter's bio
Curocell, an immunotherapy developer, is drawing investors’ attention as the company commercializes a domestic CAR-T (chimeric antibody receptor-T cell) therapy and makes a debut on the stock market in the latter half-year.According to the Korea Stock Exchange (KRX), Curocell requested a preliminary
Celltrion said it has signed a joint research and development agreement with Basgen Bio, a big data company, to strengthen its bio data analysis capabilities.Under the contract, the two companies will form a joint research committee and conduct 10 related joint research and development projects over
People Bio’s plan to supply the kit to diagnose Alzheimer’s to Singapore has hit a snag.The company said in a public filing on Thursday that its contract with Singapore’s in vitro diagnosis supplier All Eights to supply Alzheimer’s diagnosis kits has been canceled by mutual consent. The contract was
SK Bioscience on Thursday unveiled the new "SKBS 3.0" growth strategy, prioritizing the expansion of cell and gene therapy (CGT) and boosting sales of existing vaccines.In a public filing, the company unveiled its funding plan to invest about 2.4 trillion won ($1.7 billion) over the next five years
S.Biomedics, a cell therapy developer, said Wednesday that the competition rate was 994.8 to 1 in initial public offering subscriptions conducted on Monday and Tuesday.A total of 85,531 subscriptions were received for S.Biomedics’ public offering to general investors. The deposits were estimated at
Korea Biotechnology Industry Organization (Korea BIO) and the U.S. Biotechnology Innovation Organization (BIO) signed a memorandum of understanding (MOU) to promote the bioeconomy of both countries on Tuesday (local time) in Washington, DC, on the sideline of President Yoon Suk Yeol’s state visit.Th
Celltrion said it has completed a marketing authorization application for CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab), to the European Medicines Agency (EMA).Xolair, the original drug, is an antibody biologic developed by Genentech and Novartis for the treatment of allergic asth
Samsung Bioepis said SB15, a biosimilar candidate referencing Eylea (ingredient: aflibercept), demonstrated similar efficacy, safety, immunogenicity, and pharmacokinetics (PK) to the original drug in a phase 3 clinical trial. During the 2023 Annual Meeting of the Association for Research in Vision a
Biotherapeutics has obtained approval for its investigational new drug (IND) plan to conduct the phase 1.2 clinical trial of the fourth-generation EGFR-mutant non-small cell lung cancer targeted agent, BBT-207, from the U.S. Food and Drug Administration. Bridge Bio said in a public filing on Monday
Lotte Biologics said it has made an equity investment in Pinot Bio, a Korean developer of antibody-drug conjugate (ADC) platforms.Through this equity investment, the two companies plan to form a strategic business partnership and strengthen ADC platform technology development and production synergie
HLB has entered the finishing stage of splitting off its ship business sector.The company said Thursday that it has completed the procedure for its shareholders exercising claims for stock purchase to split off HLB ENG, its ship business unit.“The buyback request procedure ended without any accident